Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807 | Recruiting Phase 1 FDA Drug

• 1 other identifier: BCDI-XII
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 9

Brief Summary

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

Conditions

Von Willebrand Disease, Type 3; Concomitant VWD and Hemophilia

Outcome Measures

Primary Outcomes (2)

• Emicizumab is efficacious for prophylaxis in severe VWD & concomitant VWD/hemophilia A

  Establish bleed occurrence during treatment evaluated through descriptive statistical analysis to determine proof of principle

  18 months

• Emicizumab is safe for prophylaxis in severe VWD & concomitant VWD/Hemophilia A

  Collection of AE's, hypersensitivity reactions, thrombotic events during treatment

  18 months

Secondary Outcomes (3)

• Reduced treatment burden vs VWF/FVIII prophylaxis

  18 months

• Decreased bleed occurrence

  12 months

• Diminish bleed severity

  18 months

Other Outcomes (4)

• Improve health related QOL in study participants

  18 months

• Reduce product use for spontaneous or traumatic bleeds

  18 months

• Reduce product use during surgery

  18 months

Study Arms (1)

Open Label Emicizumab

OTHER

Emicizumab prophylaxis

Drug: Emicizumab

Interventions

Emicizumab DRUG

Subcutaneous injection of emicizumab for prophylaxis

Also known as: Hemlibra

Open Label Emicizumab

Eligibility Criteria

• Age: 0 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent
• Age 0 and older (infants weighing ≥3 kg)
• ability to comply with protocol in investigators judgement
• diagnosis of: severe VWD type 3, or VWD with VWF antigen, activity or collagen binding \</= 20 U/dl or variant VWD confirmed by genetic mutation and VWF ag, activity or CB \< 50 U/dl based on historical medical records of study site.
• diagnosis of VWD/hemophilia A defined as VWF:ag, activity or CB \<50 U/dl, and mild moderate or severe hemophilia A(defined by ISTH criteria) based on historical medical records of the study site.
• plan to be adherent to emicizumab prophylaxis during the study
• Patient's bleeding phenotype necessitating prophylaxis per treating provider recommendations.
• Patient on current prophylaxis for VWD or VWD/hemophilia A may enroll if they are currently on a non-emicizumab agent, and if it has been \> 18 months since last off-label dose of emicizumab, and are willing to discontinue current prophylaxis.
• For menstruating individuals: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year during the study period. A menstruating individual is considered to be of childbearing potential if they are post-menarchal, have not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and have not undergone surgical sterilization (removal of ovaries and/or uterus).
• Examples of highly effective contraceptive methods with a failure rate of \< 1% per year include proper use of combined oral or injected hormonal contraceptive, bilateral tubal ligation, male sterilization, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.

You may not qualify if:

• Patients and/or infants weighing \< 3 kg.
• Patients with low VWF or non-severe VWD (ie.not meeting the above criteria)
• Other concomitant bleeding disorders including coagulopathy from liver cirrhosis.
• Current treatment with emicizumab or emicizumab therapy in the previous 18 months.
• Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or current signs of thromboembolic disease
• Other conditions (e.g., certain autoimmune diseases, including, but not limited to diseases such as systemic lupus erythematosus, inflammatory bowel disease, and antiphospholipid syndrome) that may increase the risk of bleeding or thrombosis
• Patients who are at high risk for thrombotic microangiopathy (TMA; e.g., have a previous medical or family history of TMA), in the investigator's judgment
• Would refuse treatment with blood or blood products, if necessary.
• Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
• Treatment with any of the following:
• An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration before Study Day 1 A non-hemophilia-related investigational drug within the last 30 days or 5 halflives- before Study Day 1, whichever is longer An investigational drug concurrently
• History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
• Pregnant or lactating, or intending to become pregnant during the study
• Women of childbearing potential must have a negative serum pregnancy test result within 7 days before Study Day 1
• Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment

Sponsors & Collaborators

• Bleeding and Clotting Disorders Institute Peoria, Illinois: lead
• Genentech, Inc.: collaborator

Study Sites (9)

The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD)

Orange, California, 92868, United States

RECRUITING

Stanford University: Stanford Children's Health

Redwood City, California, 94063, United States

RECRUITING

University of Miami - Miller School of Medicine

Coral Gables, Florida, 33146, United States

RECRUITING

St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders

Tampa, Florida, 33607, United States

RECRUITING

Bleeding and Clotting Disorders Institute (BCDI)

Peoria, Illinois, 61614, United States

RECRUITING

Innovative Hematology, Inc. (IHI)

Indianapolis, Indiana, 46260, United States

RECRUITING

University of Michigan Medical School

Ann Arbor, Michigan, 48109, United States

RECRUITING

Central Michigan University: Children's Hospital of Michigan

Mount Pleasant, Michigan, 48859, United States

RECRUITING

Washington Center for Bleeding Disorders

Seattle, Washington, 98101, United States

RECRUITING

Related Publications (19)

• Handorf CR. Background--setting the stage for alternate-site laboratory testing. Clin Lab Med. 1994 Sep;14(3):451-8.

  PMID: 7805340 BACKGROUND

• Kaminaga T, Nishimura T, Hayashida K, Ishida Y, Hiroki M. Clinical application of spontaneous red blood cell labeling with Tc-99m sodium pertechnetate. Clin Nucl Med. 1994 Oct;19(10):895-7. doi: 10.1097/00003072-199410000-00012.

  PMID: 7805326 BACKGROUND

• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987 Feb;69(2):454-9.

  PMID: 3492222 BACKGROUND

• Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993 Dec;123(6):893-8. doi: 10.1016/s0022-3476(05)80384-1.

  PMID: 8229521 BACKGROUND

• Shima K. [Endless voyage. The life of Ms. Shin Tanaka. 6. Chapter 2]. Josanpu Zasshi. 1982 Dec;36(12):1036-43. No abstract available. Japanese.

  PMID: 6759735 BACKGROUND

• Roberts JC, Morateck PA, Christopherson PA, Yan K, Hoffmann RG, Gill JC, Montgomery RR; Zimmerman Program Investigators. Rapid discrimination of the phenotypic variants of von Willebrand disease. Blood. 2016 May 19;127(20):2472-80. doi: 10.1182/blood-2015-11-664680. Epub 2016 Feb 25.

  PMID: 26917779 BACKGROUND

• Miller CH, Hilgartner MW, Harris MB, Bussel JB, Aledort LM. Concurrence of von Willebrand's disease and hemophilia A: implications for carrier detection and prevalence. Am J Med Genet. 1986 May;24(1):83-94. doi: 10.1002/ajmg.1320240110.

  PMID: 3085499 BACKGROUND

• Casonato A, Pontara E, Boscaro M, Dannhauser D, Sartori MT, Girolami A. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion. Haematologia (Budap). 1993;25(1):57-67.

  PMID: 8339998 BACKGROUND

• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, Tanaka E, Kikuchi Y, Wakabayashi T, Wada M, Goto M, Toyoda T, Ueyama A, Suzuki S, Haraya K, Tachibana T, Kawabe Y, Shima M, Yoshioka A, Hattori K. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012 Oct;18(10):1570-4. doi: 10.1038/nm.2942. Epub 2012 Sep 30.

  PMID: 23023498 BACKGROUND

• Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.

  PMID: 27223146 BACKGROUND

• Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, Shima M. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016 Mar 31;127(13):1633-41. doi: 10.1182/blood-2015-06-650226. Epub 2015 Dec 1.

  PMID: 26626991 BACKGROUND

• Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.

  PMID: 28691557 BACKGROUND

• Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jimenez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.

  PMID: 30157389 BACKGROUND

• Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost. 2019 Sep;17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17.

  PMID: 31124272 BACKGROUND

• Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia. 2007 Sep;13 Suppl 2:16-22. doi: 10.1111/j.1365-2516.2007.01501.x.

  PMID: 17685919 BACKGROUND

• Saccullo G, Makris M. Prophylaxis in von Willebrand Disease: Coming of Age? Semin Thromb Hemost. 2016 Jul;42(5):498-506. doi: 10.1055/s-0036-1581106. Epub 2016 Jun 2.

  PMID: 27253087 BACKGROUND

• Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia. 2008 Nov;14 Suppl 5:47-53. doi: 10.1111/j.1365-2516.2008.01851.x.

  PMID: 18786010 BACKGROUND

• Federici AB. Prophylaxis in patients with von Willebrand disease: who, when, how? J Thromb Haemost. 2015 Sep;13(9):1581-4. doi: 10.1111/jth.13036. Epub 2015 Jul 28. No abstract available.

  PMID: 26081061 BACKGROUND

• Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. No abstract available.

  PMID: 30430726 BACKGROUND

MeSH Terms

Conditions

von Willebrand Disease, Type 3; Hemophilia A

Interventions

emicizumab

Condition Hierarchy (Ancestors)

von Willebrand Diseases; Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Jonathan C Roberts, MD

  Bleeding and Clotting Disorders Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sarah Kreitzer, PhD

CONTACT

309-692-5337; sarahk@ilbcdi.org

Nikki Barclay, BS

CONTACT

309-392-5337; nikki@ilbcdi.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Medical Director

Model Details: 40 patients who will receive emicizumab prophylactically

Study Record Dates

• First Submitted: August 12, 2022
• First Posted: August 15, 2022
• Study Start: November 1, 2022
• Primary Completion: December 1, 2025
• Study Completion (Estimated): June 1, 2027
• Last Updated: July 28, 2025

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (9)